Senior Director, Head of Preclinical Safety at Blueprint Medicines - Cambridge, MA, US
Senior Director, Marketing Brand Lead, AYVAKIT (avapritinib) and BLU-263
Blueprint Medicines develops kinase inhibitors for genomically defined cancer subsets of precision therapies, designed to allow patients to live longer and healthier lives.